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INTRODUCTION: 
“HYPOPHOSPHATEMIA AN UNDERDIAGNOSED ELECTROLYTE 
ANOMALY” 
Despite the fact that monitoring of sodium, potassium, and calcium ions is in 
part of the routine of intensive care unit services, very little attention has been 
devoted to phosphorus during the follow-up of critically ill patients in ICU.1 
Hypophosphatemia is frequently underestimated and there is a need for the 
emphasizes on the importance of correcting hypophosphatemia in all critically 
ill patients is needed. Hypophosphatemia is a severe metabolic derangement. It 
appears in critically ill patients, who should be followed closely and treated 
properly 101.  
Hypophosphatemia results from poor dietary intake, decreased intestinal 
absorption, increased urinary excretion and shift of phosphate from extracellular 
fluid into the interior of the cell. Severe hypophosphatemia may be found in 
diabetic ketoacidosis, respiratory alkalosis, hyper alimentation, refeeding 
syndrome and drugs such as steroids, diuretics, intravenous dextrose 
administration in patients of diabetic ketoacidosis and antacids 26,27.  
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Clinical features of hypophosphatemia include irritability, confusion, 
convulsions, coma. Rhabdomyolysis, hemolysis , leukocyte and platelet 
dysfunction, hepatic enzyme alteration and myocardial muscle dysfunction as 
well as respiratory muscle weakness and multiple organ failure 28-30. It is 
associated with increased morbidity and mortality in critically ill patients. In our 
set-up, phosphate abnormalities are also neglected, so a study is designed to see 
the prevalence of hypophosphatemia in seriously ill patients. 
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AIM OF THE STUDY 
 
1. To study the incidence of hypophosphatemia in critically ill patients in a ICU 
set up in a tertiary care hospital in Tamil Nadu. 
2. To study the co morbidities associated with hypophosphatemia. 
3. To study the predictors of hypophosphatemia in critically  ill patients. 
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REVIEW OF LITERATURE: 
Phosphorus plays an important role in metabolism as a main intracellular anion, 
enzyme constituent, and component of phosphorylated intermediate compounds, 
and phosphorus is also a component in cellular membranes, nucleic acids, and 
its proteins2,3,4. Phosphorus is a vital mineral that is usually found in nature 
combined with oxygen as phosphate. In a healthy 70-kg adult, the total body 
phosphorus content is around 700 g , of which about 80% is present in the bone 
as crystalline hydroxyapatite Ca10(PO4)6(OH)2, 9% in the skeletal muscle, 
10.9% in the viscera, and 0.1 % in the extracellular fluid. The intracellular: 
extracellular ratio is estimated to be 100:1. Most intracellular phosphate exists 
as organic phosphate compounds such as creatine phosphate and adenosine 
triphosphates (ATP), the body’s main reservoir of biochemical energy for a 
various of physiological processes.  
 
Another important intracellular phosphate store can be found in red cells as 2,3 
–diphosphoglycerate (2,3-DPG), which regulates the O2 release to tissue by 
hemoglobin in erythrocytes.  
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Phosphate homeostasis : 
Phosphate distribution  
Phosphate is a vital component of the lipid bilayer of cell membranes in the form 
of phospholipids and of other intracellular compounds like nucleic acids and its 
proteins. Phosphate is found in molecules that regulate many coenzymes, crucial 
steps in the clotting cascade, and have a role in various functions of the immune 
system. Phosphate acts as a buffer for the maintenance of plasma and urine pH.5-
9
 Phosphate is found in both organic and in-organic forms in the blood with a 
total plasma concentration of 3.9 mmol/L. The organic fraction is in the form of 
intermediary carbohydrates, lipids, and proteins. Clinical laboratory tests usually 
measure the inorganic form. The inorganic form exists for 85% as the free 
inorganic phosphate ions HPO 2 , H PO , PO 3 . 10% percent of the  inorganic 
phosphate in the blood is bound to protein and 5% complexed with calcium, 
magnesium, or sodium. At a serum pH of 7.40, the inorganic phosphate is in a 
4:1 ratio of   
HPO4 2- to H 2PO4 2-,8,9 
The normal serum concentration of inorganic phosphate is 0.80-1.45 mmol/L in 
adults. Concentrations are higher in younger age group. The concentration of 
phosphate fluctuates: there is a mean diurnal variation of 0.2 0.03 mmol/L with 
a nadir at 1100 hours, subsequently increasing to a plateau at 1600 hours and 
peaking in the early night.8,9 The plasma concentration is determined by dietary 
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intake, intestinal absorption, renal tubular reabsorption, and shifts between the 
intracellular and extracellular spaces .10 
It is absorbed in greater proportions in the jejunum, mainly by passive transport. 
Excretion takes place essentially by the kidneys, whereby 80% of the 
phosphorus is reabsorbed passively within the proximal tubule, linked with 
sodium, and regulated by hormonal action and food ingestion2,3,20. 
Approximately 1% of the body's total phosphorus reserve is found in the blood 
and phosphorus is primarily stored within  bone and teeth. Phosphorus is also 
present in soft tissues in the form of phospholipids, glycides, proteins3,20,21,22. 
Similar to that of calcium, homeostasis of phosphorus also involves direct 
participation of the intestine, bones, and kidneys, being maintained by the action 
of Vitamin D , parathyroid hormone (PTH), and calcitonin. Vitamin D acts in 
the intestine, increasing both calcium and phosphorus absorption. Phosphatemia, 
however, is controlled by renal excretion. PTH secretion, stimulated by a 
decrease in calcium serum levels, acts in renal tubular  reabsorption, reducing 
excretion of calcium while simultaneously inhibiting the reabsorption of 
phosphorus. Conversely, when calcium levels are high, calcitonin is  released 
more, acting in a reverse fashion, i.e. reducing phosphaturia while increasing 
calcium excretion23,24.  
Normal serum phosphate ranges from 2.8- 4.5mg/dl (0.4-1.8mmol/L). Serum 
levels of less than 2.5mg/dl refer to hypophosphatemia. Severe 
hypophophatemia is a serum level of less than or equal to 1.5mg/dl. Most of the 
7 
 
phosphorus is absorbed in the duodenum and jejunum. The net amount of 
phosphate absorbed from gastrointestinal tract is about 600-700mg/day. Almost 
80% of filtered load is reabsorbed along the proximal tubule, 10% in distal 
nephron and rest appears in the urine25. 
Phosphate absorption and excretion  
A selective deficiency of phosphate in the diet is unusual because of it is present 
in huge quantities in lots of foods taken in day to day life. Protein-rich foods 
(like milk products, eggs, red meat, poultry, fish) and cereal grains are rich 
sources of phosphate. The average diet provides 800-1500 mg (20-40 mmol) 
phosphate daily.  
Approximately 70% of the phosphate is absorbed in the gut, mainly in the 
duodenum and jejunum, through a sodium-dependent active transport 
mechanism stimulated by  
 Dihydroxy vitamin D (1,25 [OH] D )  and a passive mechanism with passive 
diffusion of phosphate ions. Parathyroid hormone (PTH) and low-phosphate 
diets stimulate, and diets rich in phosphate suppress intestinal absorption 
indirectly via effects on vitamin D. Low extracellular phosphate concentration 
stimulates the 25-hydroxyvitamine D3 1 - hydroxylase activity in the proximal 
tubule of the kidney thereby increasing the synthesis of 1 ,25-dihydroxyvitamin 
D3. Intestinal secretion, mainly in saliva and bile acids, adds to 200 mg of 
phosphate into the intestinal lumen daily. About 210 mg of phosphate per day is 
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exchanged between the extracellular fluid and bone as a result of bone formation 
and absorption. Under steady-state conditions, the kidney is the most important 
regulator of the serum phosphate level, make sure that urinary phosphate output 
is equivalent to the net phosphate absorption from the intestine. Phosphate is 
freely filtered across the glomerulus, and 80-90% of the phosphate is reabsorbed 
by the renal tubules. Sixty to 70% of this reabsorption occurs in the proximal 
tubule via a sodium gradient-dependent process. Three different types of 
cotransporters have been identified.10-13  
Type 1 and type 2 are located on the apical brush border membrane of the 
proximal tubular cells, whereas the type 3 cotransporters are ubiquitously 
expressed and might serve as “housekeeping” cotransporters. The type 2 
cotransporter seems to be the most important one, contributing at least 85% of 
the proximal tubular trans- port. Several factors have been identified that 
regulate the phosphate reabsorption  in the renal tubular cells19,13,14 Alterations 
in the abundance of the apical membrane type 2 cotransport protein determine 
the rate of the transport. PTH excess and high-phosphate diet cause an endocytic 
internalization of the transporters into the cell, thereby they decrease the 
reabsorption and causing phosphate excretion in the urine, whereas PTH 
deficiency and low- phosphate diet cause insertion of transporters into the 
membrane of the renal tubular cells, thereby increasing the phosphorus 
reabsorption from the renal tubules.14,17 The working site of PTH is mainly in 
the proximal tubule of the kidney. PTH binds to specific receptors in the 
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basolateral mem- brane of the renal tubules, resulting in activation of two 
pathways: cyclic adenosine monophosphate/protein-kinase-A and the 
phospholipase- 
C/calcium/protein-kinase-C systems, both of which are involved in the 
inhibition of the cotransporter of the phosphorous11 
Effect of FGF-23 on renal phosphate reabsorption: 
The serum phosphate levels of fasting mice were also significantly reduced 
compared to those of vehicle-treated animals at 8 h after injection of 4.5 micg of 
FGF-23 (vehicle: 7.65 ± 0.15 versus FGF-23: 6.22 ± 0.19 mg/dl, p < 0.001, n = 
6 each). A reduction in serum 1,25(OH)2D levels by the FGF-23 treatment was 
also observed in the same samples (vehicle: 120.84 versus FGF-23: 28.29 pg/ml, 
pooled sera, n = 6 each). These findings shows that the effects of FGF-23 on 
serum phosphate and 1,25(OH)2D are independent of intestinal phosphate 
absorption and suggest an important role of the kidney as a target organ of FGF-
23 in the regulation of the phosphate and vitamin D metabolism that controls the 
phosphate level. 
It has been demonstrated that the type IIa sodium-phosphate cotransporter 
(NaPi-2a) in the renal proximal tubules plays a pivotal role in renal phosphate 
reabsorption and its regulation. Therefore,they  next examined the effect and the 
action  of FGF-23 on type IIa sodium-phosphate cotransporter . The kidneys 
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obtained from the same groups in this study described above were pooled and 
used to prepare the BBM fractions.  
The amount of NaPi-2a protein was clearly diminished at 9 and 13 h after 
injection of  the FGF-23, when serum phosphate also decreased in FGF-23-
treated mice. Treatment of FGF-23 also reduced the renal mRNA level of NaPi-
2a at 9 h , whereas neither the mRNA levels of the type I sodium-dependent 
phosphate cotransporter in the kidney  tubules  nor the type III sodium-
dependent phosphate cotransporter (pit-1) in the bone changed. Consistent with 
the decreased expression of NaPi-2a, the fractional excretion of phosphate for 
12 h in mice injected with FGF-23 was higher than that of the vehicle-treated 
ones (vehicle: 22.6 ± 3.2% versus FGF-23: 34.3 ± 4.9%, p < 0.05, n = 4 each). 
Thus, the simultaneous reduction in serum phosphate levels and NaPi-2a amount 
in the BBM indicate that FGF-23 reduces serum phosphate by inhibiting renal 
phosphate reabsorption through the NaPi-2a. 
 
Regulation of renal vitamin D metabolizing enzymes by FGF-23 
Northern blot analysis revealed that the FGF-23 decreased the 1αOHase 
expression  in the proximal renal tubules and increased the 24OHase expression 
starting as early as 1 h after the administration. The quantitative analysis 
standardized by the expression levels of GAPDH indicated that the FGF-23 
almost halved the 1αOHase expression and increased the 24OHase expression 
by 2.5-fold . These alterations lasted more than 9 h after the administration. 
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Because 24OHase is also involved in the degradation of 1,25(OH)2D, these 
rapid changes in mRNA levels in both vitamin D-metabolizing enzymes can be 
the causative mechanism for the significant reduction in the serum 1,25(OH)2D  
level induced by FGF-23. 
Effects of FGF-23 on renal expression of vitamin D-metabolizing enzymes. 
Time course of changes in renal mRNA levels for the 1αOHase and 24OHase 
after treatment with FGF-23 or vehicle. Quantitative analysis of the relative 
abundance of 1αOHase and 24OHase mRNA to GAPDH mRNA at 1 h after 
injection. Results are means ± SEM. Statistical analysis was done by Student's 
t-test against the vehicle-treated group. 
 
PTH-independent action of FGF-23 
Although PTH is known to be a potent suppressor of NaPi-2a protein expression 
in the BBM fraction, serum PTH levels were not elevated throughout the 
examined period in this study. These results suggest that the reduction in NaPi-
2a protein observed here was not caused by PTH action. To confirm  the 
biological activity of the action FGF-23 in the proximal tubule is independent of 
PTH, we evaluated the action of FGF-23 in PTX animals. Sprague-Dawley (SD) 
rats were subjected to parathyroidectomy, and the rats exhibiting significant 
hypocalcemia and hyperphosphatemia were selected as the PTX ones for the 
following study (Ca, sham-operated: 10.30 ± 0.18 versus PTX: 6.87 ± 0.17 
12 
 
mg/dl, p < 0.001, Pi, sham-operated: 9.03 ± 0.11 versus PTX: 13.42 ± 0.30 
mg/dl, p < 0.001, n = 12 each).  
In sham-operated rats, recombinant human FGF-23 reduced serum phosphate 
and 1,25(OH)2D 12 h after the bolus injection of the FGF-23. The administration 
of  the recombinant FGF-23 to PTX rats significantly improved 
hyperphosphatemia toward the normal range and further decreased 1,25(OH)2D 
levels. These results indicates that the effects of FGF-23 on phosphate and 
vitamin D metabolism do not require PTH action. 
 
Possible mutual regulatory mechanism between FGF-23 and 1,25(OH)2D 
The study revealed that the  FGF-23 can induce rapid and significant reduction 
in serum 1,25(OH)2D levels, indicating that FGF-23 is a novel hormonal factor 
and playing a critical role in the regulation of the vitamin D metabolism in 
mammals. It is well known that 1,25(OH)2D has a feedback regulatory 
mechanism on its own serum level through increasing the expression of renal 
24OHase and decreasing that of 1α hydroxylase. The results shown above 
indicate that FGF-23 is deeply involved in the vitamin D metabolism and its 
regulation of calcium and phosphorous.  
To investigate the further involvement of FGF-23 in the regulation of the vitamin 
D metabolism, they examined whether the administration of 1,25(OH)2D could 
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be causing changes in serum FGF-23 levels using the enzyme linked immune 
sorbent system. This ELISA was originally developed for human FGF-23 and 
turned out to be applicable to rodent FGF-23. A significant elevation of serum 
FGF-23 levels was observed after  the 4 h in calcitriol-treated mice. It is 
noteworthy that even 2 or 20 nanogram  of calcitoriol, which did not change the 
serum phosphate levels at all , could evoke the elevation of the serum FGF-23 
concentration, consistent with the possibility that the serum       FGF-23 level 
could be regulated by 1,25hydroxy vitamin D. 
 
The phosphatonins  
The PTH-vitamin D axis does not suffice to explain the complexity of the 
phosphate homeostasis and regulation.14,16 Recently,  very new information has 
become available concerning factors that promote phosphate excretion. In 
patients with tumors associated with osteomalacia (tumor-induced 
osteomalacia) there is an excessive production of factors (“phosphatonins”) that 
increase renal phosphate excretion and reduce serum phosphate concentration. 
These factors are different from PTH. Their action is not impaired by a PTH 
antagonist and their effects do not appear to be mediated by cyclic adenosine 
monophosphate. The potential factors include fibroblast growth factor (FGF) 23, 
frizzled-related protein-4, and matrix extracellular phosphoglycoprotein. It has 
been demonstrated that the  fibroblast growth factor 23 and frizzled-related 
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protein-4  that can inhibit the renal tubular phosphate cotransporter.14,17 In 
patients with X-linked hypophosphatemia, there is an accumulation of the 
fibroblast growth factor 23. Patients with autosomal-dominant 
hypophosphatemic rickets produce a mutant fibroblast growth factor 23 that is 
resistant to proteloytic degradation.18  
Injection of fibroblast growth factor 23 in mice decreases type 2a cotransporters 
and suppresses the expression of the 25-hydroxyvitamin D 1 -hydroxylase.19 The 
latter action may be the reason that the adaptation mechanism of increasing the 
1 ,25-(OH)2D3 concentration in a hypophosphatemic state does not occur in 
phosphate wasting diseases in the body. 
 Phosphate turn over  
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CAUSES OF HYPOPHOSPHATEMIA 
Hypophosphatemia results from the poor dietary intake, decreased intestinal 
absorption, increased  urinary excretion and shift of phosphate from extracellular 
fluid into the  interior of the cell. Severe hypophosphatemia may be found in 
diabetic ketoacidosis, respiratory alkalosis, hyperalimentation, refeeding or  
recovery syndrome and drugs such as steroids , diuretics, intravenous dextrose 
administration in patients of diabetic ketoacidosis and antacids26,27.  
 Phosphate is frequently depleted because of the poor intake of a carbohydrate-
rich, phosphate-poor diet, as well as renal tubular phosphate wasting28. Divalent 
cation-containing antacids bind phosphate in the intestinal lumen to form 
insoluble salts and  there by preventing their absorption. Vitamin D deficiency 
also leads to decreased intestinal phosphate absorption and hence to 
hypophosphatemia. Respiratory but not the metabolic alkalosis may cause 
transient hypophosphatemia. In this disorder, intracellular pH is increased, 
thereby stimulating glycolysis, which depletes the intracellular inorganic 
phosphate pool and leads to a shifting of phosphate into cells.  
Insulin is also a strong stimulus for shifting phosphate into the interior of the 
cells. Patients with diabetic ketoacidosis are often hyper phosphatemic because 
of a shift of phosphate out of  the cells under insulinopenic conditions, but their 
total body phosphate is actually depleted as a result of urinary losses of the 
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phosphate. Subsequent treatment with insulin may uncover severe 
hypophosphatemia. Similarly, in malnourished patients whose total body 
phosphate stores may be depleted, overzealous intravenous refeeding with 
carbohydrate-rich fluids may stimulate insulin release and cause acute 
hypophosphatemia in  the body . The tyrosine kinase inhibitors imatinib, 
sorafenib, and nilotinib, which are used in the treatment of various cancers can 
cause profound hypophosphatemia, which appears to be due either to inhibition 
of bone resorption or a partial Fanconi syndrome that involves the dysfunction 
of the proximal convoluted tubule. 
Renal phosphate wasting is usually due to impaired proximal tubule phosphate 
reabsorption. In primary hyperparathyroidism , hypercalcemia is typically 
associated with  the hypophosphatemia. Fanconi syndrome is a generalized 
proximal tubule disorder characterized by hypophosphatemia in association with 
glycosuria, aminoaciduria, hypokalemia, and type II renal tubular acidosis and 
it can be caused by a variety of  the inherited metabolic disorders, multiple 
myeloma , heavy metal intoxication, and drugs such as ifosfamide, cidofovir, 
and tenofovir. Phosphaturia also can occur with  the diuretics, particularly 
carbonic anhydrase inhibitors like azetazolamide , and with antimicrobial agents 
such as pentamidine and foscarnet.  
Oncogenic osteomalacia is a paraneoplastic syndrome  associated  primarily 
with the  mesenchymal tumors that secrete a variety of phosphaturic factors 
collectively known as phosphatonins. A similar phenotype is found in X-linked 
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and autosomal dominant hypophosphatemic rickets; these inherited disorders 
are characterized by an increase in the circulating phosphatonin called fibroblast 
growth factor-23. Phosphatonins inhibit both renal tubular phosphate 
reabsorption and 1alpha -hydroxylation of 25-hydroxycholecalciferol, thereby 
leading to hypophosphatemia, rickets, or osteomalacia and inappropriately low 
serum levels of 1,25-dihydroxycholecalciferol.  
Elevation of body temperature increases intracellular utilization of phosphate in 
the glycolytic pathway, causing phosphorus to  the shift from the extracellular 
fluid into cells. For example, in one of the  study of human volunteers, a 
2°Celcius rise in temperature increased oxygen consumption by 19 
percentage 83in another study, the same rise in temperature was accompanied by 
a 26 percentage  increase in oxygen consumption and a 23 percentage  increase 
in metabolic rate 84 In rat cerebral cortex, a 1°C rise in temperature results in a 
5–6% increase in oxygen consumption, an increase in the tissue to serum glucose 
ratio, and an increase in the  intracellular glucose 6 phosphate 85 Similarly, rhesus 
monkeys infected with the  Plasmodium coatney showed both 
hypophosphatemia and an increased arteriovenous difference in glucose 
concentration, consistent with  the ncreased glucose utilization . A positive 
correlation between  the glucose disposal and oral temperature (r = 0.65, 
P<0.03) has also been observed in humans with malaria 86 Because increases in 
cellular metabolism are linearly related to temperature, the higher the 
temperature, the greater the expected intracellular shift in the phosphorus. 
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The correlation between body temperature and serum phosphorus might be 
caused by non-thermogenic effects of the  pro-inflammatory cytokines, such as 
interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-alpha, and interferon-
gamma . Increased levels of these cytokines occur in patients with malaria , 87-90 
other infectious and non-infectious causes of fever 91-92and hyperthermia. In one 
study of patients with sepsis cytokine levels were inversely related to  the serum 
phosphorus, although their relations with  the body temperature were not 
reported. In mice, injection of IL-1B, IL-6, or TNF-α leads to a significant fall 
in serum phosphorus levels. Similarly, severe hypophosphatemia was induced 
by infusion of recombinant the tumour necrosis factor in 22 patients with liver 
metastases 93 Whether this is a direct effect, or one that is mediated through a 
cytokine-induced increase in body temperature, is not known. This question 
might be resolved by studying genetic models (e.g., cyclooxygenase [COX]-2 
knockout mice) in which injection of the IL-6 does not cause fever 94 Indeed, in 
experimental acute bovine mastitis, both fever and hypophosphatemia can be 
prevented by treating animals with the ibuprofen . 
Sepsis occurs following the presence of bacteria in the circulation and is 
associated with fever, hyperthermia, and hypotension. Hypophosphatemia 
develops in the early stages of sepsis. High levels of inflammatory cytokines 
also characterize early sepsis. 
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CAUSES OF HYPOPHOSPHATEMIA  
Nutritional deficiency 
 Alcoholism 
Impaired intestinal absorption  
Antacids  
Vitamin D deficiency  
Redistribution into cells  
Respiratory alkalosis 
Insulin  
Refeeding /overfeeding syndrome 
 Burns  
Redistribution into bone  
Hungry bone syndrome  
Tyrosine kinase inhibitors- imatinib, sorafenib 
Renal losses  
Hyperparathyroidism 
 Renal tubulopathy  
Fanconi syndrome  
Drugs  including (pentamidine, foscarnet, acetazolamide)  
Phosphatonin excess syndrome  
Oncogenic osteomalacia and  Familial hypophosphatemic rickets  
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Clinical features of phosphate depletion  
Phosphate depletion can cause a variety of symptoms. Two major mechanisms 
are responsible for these symptoms are follows :a decrease in intracellular 
adenosine triphosphate (ATP) and 2,3-DPG. Symptomatic hypophosphatemia 
usually occurs when the plasma phosphate level is lower than 0.32 mmol/L . 
Hypophosphatemia may be asymptomatic under certain clinical situations like  
patients recovering from diabetic ketoacidosis and the patients with prolonged 
hyperventilation are usually without any symptoms because there is often not a 
real phosphate depletion the body.5-9,38  
  
Clinical manifestations of (severe) phosphate depletion  
1.Musculoskeletal system 
Weakness  
Myalgias  
2.Rhabdomyolysis*  
Osteopenia  
Osteomalacia  
3.Cardiovascular system** 
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 Congestive heart failure  
Arrhythmias  
4.Pulmonary system 
Respiratory failure 
Failure of weaning from ventilator  
5.Neurologic**  
Coma  
Seizures  
Encephalopathy  
Parasthesias  
6.Hematologic system**  
Hemolysis 
Leucocyte dysfunction  
Platelet dysfunction  
7.Metabolic 
Metabolic acidosis  
*Mainly in the alcoholic patient.  
**Rare manifestations and found only in case of severe phosphate depletion.  
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Skeletal muscle and bone  
Chronic phosphate deficiency may result in  the proximal myopathy, weakness 
and bone pain.39,40 However, it is important to realize that the  concomitant 
vitamin D deficiency found in a patient with hypophosphatemia can be primarily 
responsible for the symptomatology that happens. Chronic phosphate deficiency 
does not cause acute rhabdomyolysis. However, rhabdomyolysis can be found 
in patients with acute hypophosphatemia superimposed on a chronic phosphate 
deficiency. Animal experiments indicate that  the rhabdomyolysis seen with 
acute hypophosphatemia occurs in the setting of chronic hypophosphatemia and 
the muscle injury.42 
Patients with hypophosphatemia (serum phosphate 2.0 mg/dL) developed some 
degree of rhabdomyolysis in due course.42 However, the rhabdomyolysis in 
these patients was subclinical in their manifestation. Overt rhabdomyolysis in 
hypophosphatemic persons has been described mainly in chronic alcoholics, in 
whom the muscle cells are pre-injured by the alcohol and are phosphate depleted 
from the body.43 It is noteworthy to mention that the underlying 
hypophosphatemia can be masked by the release of phosphate from the injured 
muscle cells in the body.  
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Cardiovascular system  
Myocardial dysfunction due to hypophosphatemia has been described in several 
of the  reports.9,44,45-49 The impairment of the myocardial contractility has been 
attributed to a depletion of ATP in myocardial cells. Increase in mean left 
ventricular stroke work (average 44%) occurred after phosphate administration 
whose serum phosphate level ranged from 0.23 to 0.46 mmol/L. These 
improvements occurred independent of the Starling effect, suggesting an 
improvement in myocardial cell contractility.49 An improvement of the cardiac 
index (average 18%) with phosphate supplementation was found in 
hypophosphatemic patients.44 Additionally, there seems to be an association 
between hypophosphatemia and  the cardiac dysrhythmias.50,51  
Respiratory system  
Hypophosphatemia has been associated with respiratory failure and failed 
weaning from the ventilator. An obvious positive correlation   between a 
patient’s inorganic phosphate level and the maximum inspiratory pressure.52 In 
critically ill   patients hypophosphatemia causes depressed diaphragmatic 
contractions and that after the  phosphate infusion the transdiaphragmatic 
pressure showed approximately a twofold increase. There was an very excellent 
correlation between the increase in serum phosphate and the observed increase 
in diaphragmatic contractility has been observed.53  
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Several other reports have described the  patients treated with total parenteral 
nutrition (TPN) who have developed respiratory failure.54-58  
Neurological system  
A wide spectrum of  the neurological manifestations can occur.9,59 Both 
peripheral and central neuropathy have been described. The manifestations have 
most often been described in the  due course of refeeding. Paresthesia and 
tremors have been reported in patients with severe hypophosphatemia and have 
been shown to resolve with the  phosphate repletion.60-61A wide range of 
neuropsychiatric disturbances, seizures, coma, a severe neuropathy resembling 
Guillain-Barré syndrome, an acute inflammatory demyelinating 
polyneuropathy, and features resembling Wernicke encephalopathy have been 
reported.59,62-64  
Hematological sequelae  
Hemolysis has been reported in many studies.65-67 The hemolysis may be due to 
a reduction of  the ATP. The ATP depletion leads to abnormalities of the red 
blood cell membrane, changing the normally deformable cell into a rigid cells. 
Repletion with phosphate restores the red blood cell function and morphology. 
Impairment of granulocyte chemotaxis and phagocytosis have been reported. 
This finding may explain the higher incidence of Gram-negative sepsis in 
hypophosphatemic patients. Phosphate infusion increased the leucocytic ATP 
and improved the leucocytic function and regulation.68  
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Reduced platelet function has been demonstrated in dogs made 
hypophosphatemic.69  
 
Metabolic consequences  
Severe hypophosphatemia leads to mobilization of bone mineral in an attempt 
to maintain a normal serum phosphate concentration. In response to the 
phosphate depletion, the urinary phosphate loss decreases. The capacity to 
excrete the hydrogen ions as titratable acid is depressed, which can cause 
metabolic acidosis. However, mobilization of carbonate can prevent metabolic 
acidosis.  
 Overall rhabdomyolysis, erythrocyte dysfunction and hemolysis, leukocyte and 
platelet dysfunction, hepatic enzyme alteration and myocardial muscle 
derangements as well as the  respiratory muscle weakness and the  multiple 
organ failure.29,30,31 It is associated with increased morbidity and mortality in  the 
hospitalized patients. Studies have shown that hypophosphatemia is associated 
with reduced cardiac output, respiratory muscle weakness, the respiratory 
failure,33 delayed discontinuation of the ventilator, and increased hospital stay,32 
as hemolytic anemia occurs in low concentrations of serum phosphorus.34  
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Hypophosphatemia is an known cause of myopathy and rhabdomyolysis, that 
has been shown in many studies35 and is a life-threatening factor causing death 
in children with kwashiorkor.36 However, the level of complications varies with 
levels of serum phosphorus, and the first step toward the managing 
hypophosphatemic patients is to determine whether the low serum phosphorus 
level is the result of the reduced total body phosphorus or is a reflection of an 
intracellular  shift of the phosphorous.37The plasma phosphorus does not always 
indicate the total phosphorus of the body because only 1% of the body phosphate 
is extracellular compartment.  
 
EVALUATION 
The cause of hypophosphatemia is often evident from the history. If, however, 
the diagnosis is not apparent, then measurement of urinary phosphate excretion 
should be helpful. Phosphate excretion can be measured either from the  24-hour 
urine collection or by calculation of the fractional excretion of filtered phosphate 
(FEPO4) from a random urine specimen. 
 
In patients with hypophosphatemia a 24-hour urine phosphate excretion less than 
the 100 mg or a FEPO4 less than 5 percent indicates appropriate low renal 
phosphate excretion, suggesting that the hypophosphatemia is caused by internal 
redistribution (eg, refeeding syndrome, acute respiratory alkalosis) or decreased 
intestinal absorption (eg, chronic antacid therapy, steatorrhea) a 24-hour  of 
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urine phosphate excretion greater than  that or equal to 100 mg or a FEPO4 
greater than or equal to 5 percent indicates renal phosphate wasting, suggesting 
that the hypophosphatemia is caused by hyperparathyroidism, vitamin D 
deficiency, or a variety of other conditions.  
The formula used to calculate the FEPO4 is that the  same as that for the 
fractional excretion of sodium (FENa): 
 FEPO4   =   [UPO4   x   PCr   x   100]   ÷   [PPO4   x   UCr] 
where U and P refer to the urine and plasma concentrations of phosphate (PO4) 
and creatinine (Cr).  
 
Low phosphate excretion : 
In the setting of the hypophosphatemia, daily phosphate excretion should be less 
than 100 mg and the FEPO4 should be well below 5 percent (normal value is 5 
to 20 percent) if the kidney is responding normally and renal phosphate wasting 
is not the cause of the hypophosphatemia.  
 
The differential diagnosis of hypophosphatemia with an appropriately low 
urinary FEPO4 (or 24-hour urinary phosphate excretion) includes increased 
cellular uptake (internal redistribution) and reduced net intestinal absorption . 
Increased cell entry is more likely if the patient has received glucose or insulin 
infusions (as in refeeding or the treatment of uncontrolled diabetes mellitus) or 
has  the acute respiratory alkalosis (as in patients with hyperventilation). 
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In the absence of these problems, the most likely cause of the hypophosphatemia 
is decreased intestinal absorption of phosphate. Several mechanisms may 
promote a high fecal excretion of the  phosphate, including increased intestinal 
transit and secretions (as seen with chronic diarrhea), intestinal phosphate 
binding by calcium, magnesium, or aluminum to form insoluble salts (as 
observed with chronic antacid therapy), or inhibition of the intestinal phosphate 
transport (as occurs with niacin therapy) 70,71. 
 
Inappropriately high phosphate excretion: 
Urinary phosphate excretion above 100 mg/day or a FEPO4 above 5 percent is 
indicative of renal phosphate wasting in patients with hypophosphatemia. This 
problem is usually due  to either to hyperparathyroidism or to a renal tubular 
defect, both of which impair phosphate reabsorption by diminishing the activity 
of the sodium-phosphate cotransporters (NaPi-IIa and NaPi-IIc) in the proximal 
tubule 72.  
 
Hypophosphatemia can be seen with either primary or secondary 
hyperparathyroidism. The triad of hypercalcemia, hypophosphatemia, and  the 
urinary phosphate wasting is often present in primary hyperparathyroidism. By 
contrast, hypocalcemia is a major stimulus for hypersecretion of  the parathyroid 
hormone in secondary disease. Hypophosphatemia and urinary phosphate 
wasting in a patient without the hypercalcemia should prompt an evaluation for 
vitamin D deficiency.  
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Persistent hyperparathyroidism and hypophosphatemia can also occur after 
successful renal transplantation theraphy  due either both to residual parathyroid 
hormone hypersecretion by hyperplastic parathyroid glands and to persistently 
elevated plasma levels of fibroblast growth factor 23 (FGF23), a bone-derived 
phosphaturic hormone that is markedly elevated in  the patients with kidney 
disease.  
 
Tubular defects, which are relatively rare, can occur either as an isolated 
impairment in proximal phosphate transport (as seen in hypophosphatemic 
rickets or tumor-induced osteomalacia) or as a generalized defect in proximal 
function (called the Fanconi syndrome) .The Fanconi syndrome is typically 
accompanied by a clinical evidence of other abnormalities in proximal 
reabsorption, including glucosuria (at a normal plasma glucose concentration), 
hypouricemia, aminoaciduria, and a hyperchloremic metabolic acidosis due to 
the  urinary bicarbonate wasting. 
 
 Among the major causes of the Fanconi syndrome are cystinosis, Wilson's 
disease, multiple myeloma (in which filtered light chains are toxic to the 
proximal tubule), heavy metal toxicity, and medications (particularly nucleotide 
analog  of  reverse transcriptase inhibitors, such as tenofovir, and ifosfamide).  
Isolated urinary phosphate wasting is rare but can be observed in patients 
receiving ferric carboxymaltose therapy for treatment of iron deficiency anemia 
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73
, in children with certain genetic mutations leading to the vitamin D-resistant 
rickets, or in adults with oncogenic osteomalacia, a condition characterized by 
the overproduction of phosphaturic substances from a mesenchymal tumor 
(usually a hemangiopericytoma).  
One clue to the presence of oncogenic osteomalacia is a very low plasma 
calcitriol level (1,25-dihydroxyvitamin D).  
 
Normally, hypophosphatemia results in stimulation of calcitriol levels, which 
would tend to raise the serum phosphate by increasing the  intestinal phosphate 
absorption and, perhaps, via bone resorption. Thus, the low calcitriol levels 
produced by oncogenic osteomalacia are counterintuitive in nature.  
 
TREATMENT  
 While overt symptoms of hypophosphatemia rarely occur unless the serum 
phosphate concentration is less than 2 mg/dL (0.64 mmol/L), some evidence 
suggests that even mild hypophosphatemia may be associated with poor clinical 
outcomes 74. Serious symptoms such as muscle weakness and rhabdomyolysis 
are generally not observed until the serum phosphate concentration falls below 
1 mg/dL (0.32 mmol/L) 75,76.  
 
For  some of these reasons, most hypophosphatemic patients will not require 
therapy other than that aimed at the underlying cause. 
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Hypophosphatemia occurring during the correction of diabetic ketoacidosis will 
correct spontaneously with normal dietary intake. Trials of routine phosphate 
supplementation have not shown benefit, but such therapy may be warranted in 
patients with severe symptomatic hypophosphatemia.  
 
Patients who have hypophosphatemia due to gastrointestinal losses should 
correct spontaneously once there is resolution of the underlying cause (eg, 
diarrhea, chronic antacid therapy, or vitamin D deficiency which should be 
treated with vitamin D supplementation). Specific recommendations for the 
vitamin D supplementation can be done. 
 
Phosphate repletion regimens — approach to phosphate repletion takes into 
account the serum phosphate concentration, the presence or absence of the overt 
symptoms of hypophosphatemia, and whether the patient can take oral therapy. 
If possible, we prefer oral rather than intravenous phosphate therapy since 
intravenous repletion can lead to hyperphosphatemia that may result in serious 
complications such as hypocalcemia, acute kidney injury, and arrhythmias.  
 
In asymptomatic patients with a serum phosphate less than the  
2.0 mg/dL (0.64 mmol/L), we give oral phosphate therapy since many of these 
patients have myopathy and weakness that are not clinically apparent.The 
treatment of symptomatic patients varies with the severity of the 
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hypophosphatemia. Treat with oral phosphate if the serum phosphate is 1.0 to 
1.9 mg/dL (0.32 to 0.63 mmol/L).  
 
 
Treat with intravenous phosphate if the serum phosphate is less than 
1.0 mg/dL (0.32 mmol/L) and switch to oral replacement when the serum 
phosphate exceeds 1.5 mg/dL (0.48 mmol/L). Stop phosphate repletion when 
the serum phosphate is greater than or equal to 2.0 mg/dL (0.64 mmol/L) unless 
there is an indication for chronic therapy such as persistent urinary phosphate 
wasting. 
 
Oral repletion is most often achieved with a combined preparation of sodium 
and potassium phosphate; sodium phosphate is preferred for intravenous 
therapy. 
 
 
Oral dosing :  
 
When oral dosing is used,  initiate therapy with  the 30 to 80 mmol of phosphate 
per day in divided doses. Phosphate may also be supplemented with skim milk, 
which contains approximately 15 mmol of phosphate per 480 mL serving. 
The following regimen is a reasonable approach 77: 
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1. If the serum phosphate is greater than or equal to 
1.5 mg/dL (0.48 mmol/L), 1 mmol/kg of elemental phosphorus 
(minimum of 40 mmol and a maximum of 80 mmol) can be given in three 
to four divided doses over a 24-hour period. 
2. If the serum phosphate is less than 
1.5 mg/dL   (0.48 mmol/L), 1.3 mmol/kg of elemental phosphorus (up to 
a maximum of 100 mmol) can be given in three to four divided doses 
over a 24-hour period. 
3. Severely obese patients may receive the maximal initial doses or an 
adjusted dose based upon their height and weight  
4. Patients with a reduced glomerular filtration rate should receive 
approximately one-half of the suggested initial dose. 
 
The serum phosphate concentration should be rechecked 2 to 12 hours following 
the last of the divided doses to determine whether repeated doses are required. 
If so, the same approach may be reapplied. 
 
Oral phosphate supplements (tablets and powders) contain varying ratios of 
sodium and potassium phosphate. Serious medication errors have occurred due 
to confusion among preparations and lack of uniformity of units on product 
labels and when ordering. Thus, an oral phosphate supplement should be 
selected with the consideration of its potassium and sodium content and dosed 
according to mmol of phosphate.  
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Commonly used oral potassium phosphate-sodium phosphate supplements 
include 250 mg (8 mmol) of phosphate per tablet. 
 
Intravenous dosing : 
 
Intravenous phosphate is potentially dangerous since it can precipitate with 
calcium and produce a variety of adverse effects including the hypocalcemia due 
to binding of calcium, renal failure due to calcium phosphate precipitation in the 
kidneys, and possibly fatal arrhythmias. 
If intravenous therapy is necessary in patients with severe symptomatic 
hypophosphatemia or an inability to take oral therapy, we suggest a dose that 
varies depending upon the severity of the hypophosphatemia and the weight of 
the patient.78,79: 
 
1. If the serum phosphate concentration is greater than or equal to 
1.25 mg/dL (0.40 mmol/L), we give 0.08 to 0.24 mmol/kg over six hours 
(up to a maximum total dose of 30 mmol) 
 
2. If the serum phosphate concentration is less than 
1.25 mg/dL (0.40 mmol/L), we give 0.25 to 0.50 mmol/kg over 8 to 12 
hours (up to a maximum total dose of 80 mmol) 
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3. Other investigators have advocated a more aggressive approach since, in 
critically ill patients receiving nutritional support, lower doses similar to 
those above were not effective. This strategy was evaluated in a study of 
79 critically ill trauma patients with hypophosphatemia 80 .The following 
algorithm was used for dosing: 
 
4. If the serum phosphate was 2.3 to 3.0 mg/dL (0.73 to 
0.96 mmol/L), 0.32 mmol/kg was given 
 
5. If the serum phosphate was 1.6 to 2.2 mg/dL (0.51 to 
0.72 mmol/L), 0.64 mmol/kg was given 
 
6. If the serum phosphate was less than 
1.6 mg/dL (0.50 mmol/L), 1.0 mmol/kg was given 
 
Each dose was rounded to the nearest 7.5 mmol for ease of preparation and was 
infused at 7.5 mmol per hour. If hypophosphatemia persisted on subsequent 
days, additional doses were given according to this strategy. On day 3, the serum 
phosphate was normal in all 79 patients. This dosing regimen appeared to be 
safe; mild hyperphosphatemia was noted only eight times in 237 patient-days, 
and there were no instances of hypocalcemia. 
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However, none of the patients in this study had  a renal function impairment, a 
setting in which aggressive replacement should  be generally be avoided. In 
addition, do not usually give phosphate replacement when the serum phosphate 
is above 2.0 mg/dL(0.64 mmol/L). 
 
The serum phosphate concentration should be monitored every six hours when 
intravenous phosphate is given, and the patient should be switched to oral 
replacement when the serum phosphate concentration reaches 
1.5 mg/dL (0.48 mmol/L) 81. 
 
Urinary phosphate wasting — Hypophosphatemia due to persistent urinary 
phosphate wasting is more difficult to treat than the other causes of 
hypophosphatemia since raising the serum phosphate concentration with 
phosphate supplements will result in a further increase in phosphate excretion 
that minimizes the elevation in serum phosphate. 
 
Another possible approach to the treatment of urinary phosphate wasting is the 
administration of dipyridamole. The observation that acute administration of 
dipyridamole increases renal phosphate reabsorption in animals and humans 
prompted a prospective study evaluating its efficacy in 64 patients with 
idiopathic increased urinary phosphate losses and mild hypophosphatemia 82. 
Exclusion criteria included hypercalcemia, a history of cardiovascular disease, 
a glomerular filtration rate of less than 70 mL/min per 1.73 m2
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were primarily focused on identifying patients with specific causes of phosphate 
wasting. 
 
The administration of dipyridamole (75 mg four times daily) significantly 
increased the serum phosphate levels in 80 percent of patients, with the 
maximum effect occurring after nine months of therapy. Serum levels of 
parathyroid hormone and calcium were unchanged, but the concentration of the  
calcitriol (1,25-dihydroxyvitamin D) was significantly decreased.  
 
1.According to Chermesh I, Meshulam C, Tamir A, Eliakim R, Levy Y, in their 
study they observed, there was a higher proportion of the obese patients in the 
moderate hypophosphatemia group. There was a higher proportion of patients 
who consumed alcohol on a regular basis before hospitalization in the extreme 
hypophosphatemic group. Patients suffering from the extreme 
hypophosphatemia were more likely to be hospitalized in the intensive care unit 
and ventilated on hospitalization. Length of hospitalization was longer for the 
extreme hypophosphatemia group than for the moderate hypophosphatemia 
group. When comparing the group outcomes it was found that more patients with 
severe hypophosphatemia died in their course in hospital 101. 
2.Sibille .M in his study concluded that hypophosphatemia with or without 
phosphorus depletion can be observed in variety of  diseases--particularly 
diabetic ketoacidosis, respiratory alkalosis, alcoholism, parenteral nutrition and 
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hyperalimentation--and may cause serious neurologic, muscular, and 
hematologic disorders and suggested that some place can be reserved for the 
serum phosphate in systematic and emergency panels of blood investigations.102 
3. Juan D, Elrazak MA  in their study observed that hypophosphatemia is 
common in hospitalized patients and occurs under a variety of circumstances 
other than parathyroid hormone excess alone. The effect of dextrose ingestion 
on serum phosphate level was shown in one normal patient. Whenever 
carbohydrate was administered intravenously (45 cases), this was considered the 
primary cause of the hypophosphatemia. Other causes were as follows: diuretics, 
hyperalimentation, alcoholism, respiratory alkalosis, dialysis, insulin, 
corticosteroids, diabetic ketoacidosis, vomiting, phosphate-binding antacid, 
Gram-negative sepsis, primary hyperparathyroidism, saline, epinephrine, 
gastrointestinal malabsorption, and unknown. Hypophosphatemia in 
hospitalized patients may have various causes.103 
4.Knochel JP  after his study concluded that severe hypophosphatemia may be 
observed after the ingestion of certain antacids which can  complex phosphorus 
in the intestinal lumen. In severe burn cases, during refeeding after denutrition, 
during intense and prolonged hyperventilations responsible for respiratory 
alkalosis, in diabetic ketoacidosis and in alcoholics. Hypophosphatemia lead to 
erythrocyte abnormalities which may eventually approach hemolysis 
intravascular, to phagocytosis and platelet function disorders and to neurological 
complications which suggest a metabolic encephalopathy, a myopathy, a 
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metabolic acidosis or a change in hepatic functioning. Treatment for 
hypophosphatemia with milk and sodium or potassium phosphate must be begun 
as soon as possible and must be sufficient to maintain blood phosphate levels 
above 10 mg/liter.104 
5.Talakoub R, Bahrami M, Honarmand A, Abbasi S, Gerami H in their study 
observed that there were significant differences between serum Phosphorous 
concentration on admission to ICU, at the time of connecting to ventilator  and 
weaning from ventilator  between two groups and this difference was significant 
(P < 0.001). They found that the best cut-off point of 3.07 for serum 
Phosphorous concentration to predict the longer duration of Mechanical 
ventilation. According to the results of their study, hypophosphatemia may 
increase the need to MV. Therefore, monitoring serum Phosphorous level is a 
good prognostic factor to predict the need to ventilation.105 
6.Zhao Y, Li Z, Shi Y, Cao G, Meng F, Zhu W, Yang GE  investigated the effect 
of hypophosphatemia on the withdrawal of MV in patients with the acute 
exacerbations of chronic obstructive pulmonary disease (AECOPD). The results 
showed that the morbidity rate of hypophosphatemia in these 
AECOPD patients was 56.72%. A significantly higher percentage of the failure-
to-wean from MV was observed in the hypophosphatemia group vs. the 
normophosphatemic group (34.21 vs. 10.34%, P<0.05). 
Furthermore, hypophosphatemia was associated with the  respiratory muscular 
weakness, as reflected by a decrease in the tidal volume of spontaneous 
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respiration, reduced static lung compliance and impaired pulmonary function, 
leading to weaning failure from ventilators. The findings suggested 
that hypophosphatemia significantly affected the weaning from MV in 
AECOPD patients. Serum phosphorus levels may therefore serve as a reference 
index to determine the success of weaning.106 
7.El Shazly AN, Soliman DR, Assar EH, Behiry EG, Gad Ahmed IAEN studied  
the incidence of hypophosphatemia in critically ill children, its association with 
clinical outcomes and the possible risk factors. They enrolled 50 patients in their 
study. Levels of serum phosphate were measured on  the day 1 and the  day 7 of 
PICU (Pediatric intensive care unit) stay. The following variables were 
analyzed: age, gender, diagnosis on admission, malnutrition, phosphorus intake, 
clinical severity score on admission OFI (Organ Failure Index) and daily scores 
PELOD (Pediatric Logistic Organ Dysfunction), sepsis, use of dopamine, 
furosemide and corticosteroids and assessment of nutrition by z scores. 
 And they found out that the incidence of hypophosphatemia on admission was 
42%. On seventh day of admission incidence of hypophosphatemiawas 62%. 
Malnutrition was present in 24% of the patients, serum phosphorus level was 
significantly lower in malnourished than in well-nourished children                                   
(p value = 0.018). Hypophosphatemia was associated with prolonged PICU 
length of stay (p < 0.001) but was not associated with increased mortality 
(p = 0.13).  
41 
 
Cases on the parenteral nutrition and insufficient oral intake while on 
mechanical ventilator significantly 
showed    hypophosphatemia  (p = 0.017). Hypophosphatemia was associated 
with the use of furosemide, dopamine, steroids and β2 agonist.107 
 
8. Kilic O, Demirkol D, Ucsel R, Citak A, Karabocuoglu M have done a 
retrospective review of the medical records of children admitted to the 
pediatric intensive care unit from December 2006 to December 2007, in order 
to determine the prevalence of hypophosphatemia and to discuss the clinical 
implications of hypophosphatemia in critically ill children. In 60.2% (n = 71) 
of the patients, any serum phosphorous level at admission and at the third day 
or seventh day after admission to pediatric intensive care unit was in the 
hypophosphatemic range.  
    Sepsis was present in 22.9% (n = 27) of the children studied and was 
associated with the  hypophosphatemia (P = .02). Hypophosphatemia was 
also associated with use of furosemide (P = .04), use of steroid (P = .04), use 
of β(2) agonist (P = .026), and use of an H(2) blocker (P = .004). There was 
a significant association between hypophosphatemia and the rate to attain 
target caloric requirements by enteral route (P = .007). The median time to 
attain  the target caloric requirements by enteral route was 2.9 ± 1.9 (0.2-10) 
days in the normophosphatemic group and 4.4 ± 2.8 (0.3-12) days in the 
hypophosphatemic group. In the multiple regression model, solely the rate to 
42 
 
attain the target caloric requirements by enteral route demonstrated 
independent association with hypophosphatemia (P = .006; β = .27; 95% 
confidence interval, 0.02-0.09).  
Significant association was found between hypophosphatemia and the duration 
of mechanical ventilation and between hypophosphatemia and pediatric 
intensive care unit length of stay (P = .02 and P = .001, respectively). They 
concluded that critically ill pediatric patients were prone to devolep 
hypophosphatemia, especially if they cannot be fed early by enteral route.  
Hypophosphatemia is associated with an increased duration of mechanical 
ventilation and increased length of stay in the pediatric intensive care unit, 
suggesting that active repletion might improve these parameters.108 
9.Giovannini I, Chiarla C, Nuzzo G. conducted a study to assess 
pathophysiologic correlates of hypophosphatemia and the simultaneous 
relationship with clinical events after hepatectomy. A total of 333 measurements 
were obtained in 59 patients, these were performed preoperatively and at post 
operative  days 1, 3, and 7 in all patients, and subsequently, until recovery or 
death, only in those with complications. Measurements included plasma 
phosphate together with a large number of additional blood chemistries, taking 
into account primary and the  associated diseases, events associated with the 
operation, doses of parenteral substrates, occurrence of sepsis or other post 
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operative complications, outcome, and a consistent set of complementary 
variables.  
Plasma phosphate decreased at p.o. days 1 and 3 (P < 0.001) and resumed 
to a level close to baseline at p.o. day 7. Regression analysis showed that 
phosphate was related simultaneously to patient age (inversely), levels of 
creatinine and potassium (directly), and dose of parenteral amino acids 
(inversely; P < 0.001 for all). Independently of covariation with these variables, 
there was a decrement in phosphate at p.o. days 1 and 3 that was related 
specifically to p.o. condition; this decrement had a general component common 
to all patients, an additional component related to duration of previous hepatic 
ischemia at surgery, and a further component predictive of the subsequent 
development of complications (in mostof the  cases, sepsis).  
          Plasma phosphate at p.o. day 1 was related inversely to APACHE II score 
(r2 = 0.4, P < 0.001), and levels lower than 1.5 mg/dL were associated with an 
almost 4-fold increase in the rate of complications compared with cases with 
higher phosphate (P < 0.001). The best single variable bridging the early 
evidence of hypophosphatemia to subsequent development of complications 
was plasma cholesterol, which fell significantly from p.o. day 3 onward 
in patients with complications compared with those recovering normally                      
(P<0.01), and in non survivors compared with survivors (P < 0.01) 
. Hypophosphatemia may anticipate clinical evidence of complications by 
reflecting an early stronger acute-phase response, with shift of phosphate from 
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intra- vascular to extravascular space, or true phosphorus deficiency, which may 
favour development of complications by impairing high-energy substrate 
availability for host defence and other cell functions.109 
 
10.Marik PE, Bedigian MK conducted a study to determine the incidence, risk 
factors, and clinical impact of refeeding hypophosphatemia in the heterogeneous 
group of patients in an ICU. Sixty-two patients in the ICU who were refed after 
being starved for at least 48 hours were prospectively followed up. Each patient 
had a nutritional assessment prior to the initiation of nutritional support. Serum 
phosphate, magnesium, and calcium levels were measured at he baseline, and 
these measurements were repeated daily. Refeeding hypophosphatemia was 
considered to have developed  in patients whose serum phosphorus level fell by 
more than 0.16 mmol/L to below 0.65 mmol/L.  
 
Twenty-one patients (34%) experienced refeeding hypophosphatemia. In 
6 patients, the serum phosphorus level fell below 0.32 mmol/L. The only risk 
factor studied that could predict the development of hypophosphatemia was the 
serum prealbumin  concentration not the albumin (mean +/- SD, 127 +/- 34 vs 
79 +/- 40 g/L, P < .001). Seventeen (81%) of these 21 patients in 
whom hypophosphatemiadeveloped had a prealbumin concentration less than 
110 g/L compared with that in 12 (30%) of the patients who did not experience 
this complication (P < .001).  
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In those patients in whom refeeding hypophosphatemia developed, the serum 
phosphorus level reached a mean +/- SD nadir of 1.9 +/- 1.1 days after feeding 
was started. Although the Acute Physiology and Chronic Health Evaluation II 
score was similar, the length of mechanical ventilation  and the length of hospital 
stay were significantly longer in those patients who had 
experienced hypophosphatemia compared with those patients who did not 
experience this complication.  
Refeeding hypophosphatemia occurs commonly in critically ill patients in the 
ICU. Starvation for a period as short as 48 hours and poor nutritional status 
predispose to this refeeding syndrome. Patients at risk should be refed slowly, 
and the serum phosphorus level should be closely monitored and supplemented 
as required.110 
 
11. Lee JL, Sibbald WJ, Holliday RL, Linton AL, studied 3 cases and found that 
severe hypophosphatemia and profound coma are associated . Although the 
occurrence of hypophosphatemia appeared to coincide with a high rate of 
intravenous administration of dextrose  and water, two of the three patients had 
liver disease and the other had hypothermia. In two instances the neurologic 
status improved with intravenous phosphate therapy. These case reports 
emphasize the importance of the early recognition and treatment of 
profound hypophosphatemia in critically ill patients in ICU.111 
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12. Richard Haber, Warren Browner , Department of Medicine, University of 
California, San Francisco, United States of America, obsevered that 
hypophosphatemia occurs in 40 to 60% of patients with acute malaria, and in 
many other conditions associated with elevations of the  body temperature. To 
determine the prevalence and causes of the hypophosphatemia in patients with 
malaria, they retrospectively studied all adults diagnosed with acute malaria 
during a 12-year period. To validate their findings, they analyzed a second 
sample of malaria patients during a subsequent 10-year period. Serum 
phosphorus correlated inversely with temperature (n = 59, r = 20.62; P,0.0001), 
such that each 1C increase in body temperature was associated with a reduction 
of 0.18 mmol/L (0.56 mg/dL) in the serum phosphorus level (95% confidence 
interval: 20.12 to 20.24 mmol/L [20.37 to 20.74 mg/dL] per 1C).  
 
A similar effect was observed among the 19 patients who had repeat 
measurements of serum phosphorus and temperature. In a multiple linear 
regression analysis, the relation between the  temperature and serum phosphorus 
level was independent of blood pH, PCO2, and serum levels of potassium, 
bicarbonate, calcium, albumin, and glucose. Their study demonstrated a strong 
inverse linear relation between body temperature and the serum phosphorus 
level that was not explained by other factors known to cause hypophosphatemia. 
If causal, this association can account for the high prevalence of 
hypophosphatemia, observed in our patients and in previous studies of patients 
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with malaria. Because hypophosphatemia has been observed in other clinical 
conditions characterized by fever or hyperthermia, this relation may not be 
unique to malaria alone. Elevation of body temperature should be added to the 
list of causes of hypophosphatemia.  
13.Vivian Barak  MDA, Audrey Schwartz MDB, Inna Kalickman  MDA, 
Benjamin Nisman MDA, Gaby  Gurman  MDB, Yehuda  Shoenfeld MDC have 
done a study  to correlate hypophosphatemia with cytokines and cytokine 
receptor levels during early sepsis. They  aimed to re establish the results 
obtained from the  patients in an in vivo experimental model, in order to 
understand the mechanism of hypophosphatemia induction in the early sepsis.  
Ninety-nine patients were enrolled in their study and their clinical condition was 
classified as the presence of infection, sepsis, and bacterial growth in their blood 
cultures. Phosphate levels and cytokine levels were recorded. In order to 
determine whether hypophosphatemia is correlated to the increased 
inflammatory cytokines, they injected  a normal mice with recombinant 
cytokines and studied their effect on phosphate levels. Their  results revealed 
that 80% of the septic patients had hypophosphatemia associated with very high 
levels of the tumor necrosis factor (TNF) alpha and interleukin (IL)-6 and of 
soluble IL receptor (sIL)-2R and IL-6R, especially in those patients with positive 
blood cultures.  
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Injection of IL-6, TNF alpha and IL-1beta  in mice markedly decreased the 
phosphate serum levels. Significant associations were demonstrated between the 
high levels of inflammatory cytokines and their receptors and between the serum 
phosphate levels, especially in patients with positive blood culture. Their results 
point to the correlation between the high inflammatory cytokines levels and 
hypophosphatemia during early sepsis. Cytokine levels and hypophosphatemia 
may be included in the sepsis evaluation and prognosis. Anti cytokine strategies 
might, therefore, reverse hypophosphatemia and other parameters of sepsis.112 
14. Carroll JL, Kanter RK,  retrospectively studied 42 patients with Reye's 
syndrome to determine the frequency and degree of hypophosphatemia, to 
identify the  possible causes, and to determine whether the 
hypophosphatemia was related to the severity of disease or the mortality. 
Nineteen (46%) patients were hypophosphatemic at the time of hospital 
admission. Five of these had a serum phosphorus level less than 2.5 mg/dl and 
three were 1.5 mg/dl or less. During the subsequent hospital course, 32 
(78%) patients developed hypophosphatemia. It was of moderate degree (2.5 
mg/dl or less) in 20 patients, and was severe (1.5 mg/dl or less) in eight patients. 
 Hypophosphatemia correlated with concurrent hyperglycemia but not with 
other potential causes studied. The degree of hypophosphatemia during 
treatment roughly paralleled the severity of illness but was not a predictor of 
outcome. The need for treatment of hypophosphatemia in Reye's syndrome has 
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not been established, and hypocalcemia as a complication of excess phosphate 
infusion should be avoided.113 
15. Aubier M, Murciano D, Lecocguic Y, Viires N, Jacquens Y, Squara 
P, Pariente R  studied the effects of the hypophosphatemia on diaphragmatic 
function in eight patients with acute respiratory failure who were artificially 
ventilated. Their mean serum phosphorus level was 0.55 +/- 0.18 mmol per liter 
(normal value, 1.20 +/- 0.10). The contractile properties of the diaphragm were 
assessed by measuring the transdiaphragmatic pressure generated at the 
functional residual capacity during bilateral supramaximal electrical stimulation 
of the phrenic nerves. Diaphragmatic function was evaluated in each patient 
before and after the  correction of hypophosphatemia, which was achieved by 
administration of 10 mmol of phosphorus (as KH2PO4) as a continuous infusion 
for four hours. After phosphate infusion, the mean serum phosphorus level 
increased significantly (1.33 +/- 0.21 mmol per liter, P less than 0.0001). The 
increase in serum phosphorus was accompanied by a marked increase in the 
transdiaphragmatic pressure after phrenic stimulation (17.25 +/- 6.5 cm H2O as 
compared with 9.75 +/- 3.8 before phosphate infusion, P less than 0.001). 
Changes in the serum phosphorus level and transdiaphragmatic pressure were 
well correlated (r = 0.73). These results strongly suggest 
that hypophosphatemia impairs the contractile properties of the diaphragm 
during acute respiratory failure, and they emphasize that  the importance of 
maintaining normal serum inorganic phosphate levels in such patients.114 
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16. Schwartz A, Gurman G, Cohen G, Gilutz H, Brill S, Schily M, Gurevitch 
B, Shoenfeld Y conducted a study  to evaluate a possible association between 
serum phosphate levels and the incidence of cardiac arrhythmias in the early 
stages of sepsis. It is a prospective, controlled study in the General Intensive 
Care Unit (GICU) of a university hospital. Sixteen patients with sepsis, but 
without any previous cardiac disease, were studied during their first 24 h in the 
GICU. Patients were connected to a continuous ECG recording device. Blood 
samples for serum phosphate level determinations were drawn during the first 6 
h after admission to the unit. Ten of 16 patients had 21 episodes of atrial and 
ventricular arrhythmias in their course in hospital .  
These patients had higher mean Apache II scores (20.2+/-6.2) than the 
six patients without arrhythmias (13.2+/-1.7; P<0.05) and significantly lower 
mean phosphate levels (0.73+/-0.16 vs. 1.02+/-0.32 mmol/l; P<0.03). No 
association was found between serum phosphate levels and mortality 
among patients with arrhythmias, or when all survivors (with and without 
arrhythmia) were compared to all  the non-survivors. These results indicate 
that patients with sepsis and low serum phosphate levels are at a greater risk of 
developing cardiac arrhythmias.  
They suggested  that phosphate supplementation in the early stages of sepsis 
may prevent the  cardiac arrhythmias.115 
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17. Thomas M. O’Brien, MD, and LeAnn Coberly, MD in their study observed 
severe hypophosphatemia in respiratory alkalosis. In respiratory alkalosis as 
carbon dioxide (CO2) decreases, intracellular CO2, which is readily diffusible 
across the cell membrane, moves into the plasma. The loss of catbon dioxide  
from the cell causes the intracellular pH to rise. This rise in the pH stimulates 
glycolysis, which requires phosphate ions to make adenosine triphosphate. This 
phosphate is obtained from circulating inorganic phosphate stores, which are 
readily diffusible across the cell membrane. The serum phosphate concentration 
falls as a result of the intracellular phosphate shift. In contrast, in metabolic 
alkalosis the intracellular pH does not rise because bicarbonate is poorly 
diffusible across the cell membrane. There is no increase in intracellular 
glycolysis, no need for influx of the phosphate from within and outside of the 
cell, and the extracellular space maintains its phosphate concentration.  
In the case presented, respiratory alkalosis best explains the severe 
hypophosphatemia. The patient had no other contributing factors that would 
account for the phosphate abnormality. Treatment of the patient’s 
hyperventilation allowed for resolution of the respiratory alkalosis and 
contributed to normalization of the hypophosphatemia. Though the effect of the 
abbreviated phosphate infusion on the serum phosphate concentration in the 
blood is difficult to ascertain, the rapid correction in the event  of profound 
hypophosphatemia and  points to phosphate redistribution as a major 
mechanism.  
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18. Cynthia lim and her colleagues studied adverse effects of hypophosphatemia 
acute kidney injury patients undergoing haemodialysis. Critically ill patients 
receiving care in the ICU may experience hypophosphatemia due to 
malnutrition, refeeding syndrome, severe sepsis, or use of insulin and parenteral 
nutrition. 
 In addition, RRT removes phosphate from plasma Earlier studies evaluated only 
moderate to severe hypophosphatemia in ICU patients who may not be receiving 
RRT or were conducted in patients receiving only CRRT .An Australian study 
found that hypophosphatemia <0.6 mmol/L was associated with increased 
need and longer duration of mechanical ventilation while Demirjian et al. 
established that serum phosphate <2 mg/dL (0.67 mmol/L) during CRRT 
was associated with an increased need for tracheostomy [adjusted OR 1.81, 95% 
CI (1.07, 3.08)] . However, in clinical practice, patients requiring acute RRT 
may receive either continuous, intermittent or both modalities.  
Their  study showed that even mild hypophosphatemia (serum phosphate cut off 
of 0.94 mmol/L) during acute RRT, regardless of dialysis modality, was 
associated with the prolonged mechanical ventilation in the hospital stay. The 
clinical impact of hypophosphatemia on mortality and hemodynamic is less 
clear. Our study found no significant association between hypophosphatemia 
during RRT and mortality or need for prolonged vasopressor support, 
confirming the results of other multivariate analyses. This observation suggests 
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that hypophosphatemia may be a marker of illness severity rather than a 
predictor of mortality. 
Factors associated with hypophosphatemia during acute dialysis 
Serum phosphate level at RRT initiation was associated with hypophosphatemia 
during RRT in our study, although this was not consistently found in earlier 
studies. Other authors have previously identified RRT intensity and duration, as 
risk factors for hypophosphatemia during CRRT.  
In a secondary analysis by Bellomo et al., higher intensity CRRT (effluent flow 
rates of 40 mL/kg/h versus 25 mL/kg/h) was independently associated with the  
hypophosphatemia. Among our patients who received only CRRT, patients with 
hypophosphatemia did tend to have higher average effluent flow rate [36.1 (31.3, 
44.8) mL/kg/h versus 29.9 (26.0, 36.9) mL/kg/h, P = 0.08], but this was not 
statistically significant. Hypophosphatemia was associated with longer duration 
of CRRT , but not with longer sessions (10 h versus 6 h) of intermittent RRT.  
Although Ratanarat et al. found that total phosphate removal was greater in 
CRRT than intermittent RRT (66.7 ± 18.9 mmol compared with 
29.9 ± 7.7 mmol, P = 0.001), clinical hypophosphatemia was not 
significantly different between continuous and intermittent modalities. 
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Prevention and treatment of hypophosphatemia during acute dialysis 
Despite their existing phosphate repletion protocol in CRRT, a large proportion 
still  need to be developed  for hypophosphatemia. Troyanov et al. advocated 
addition of phosphate to conventional phosphate-free dialysate and replacement 
fluid when serum phosphate level was <1.50 mmol/L to prevent 
hypophosphatemia in patients receiving CRRT for more than 24 h. 
Alternatively, commercially prepared phosphate-containing solutions such as 
Phoxilium (Gambro Lundia AB, Lund, Sweden) may effectively prevent 
hypophosphatemia in patients receiving the  CRRT . Currently, there is no 
randomized controlled evidence or consensus as to the optimal serum phosphate 
target in critically ill patients . Hypophosphatemia was generally corrected if it 
was symptomatic or severe , with phosphate repletion therapy  to achieve 
physiological levels.  
However, some authors contest that phosphate repletion based on serum levels 
may not correlate with intracellular concentrations and ATP synthesis. Others 
were concerned about the risks of adverse effects of phosphate replacement, 
such as hypocalcemia, arrhythmia and renal injury, especially with aggressive 
replacement. Although intravenous phosphate replacement was shown by recent 
studies to be safe in critically ill patients, these studies generally excluded 
patients with severe renal impairment. Given our findings that even mild 
hypophosphatemia was associated with prolonged need for mechanical 
ventilation among patients with AKI receiving acute RRT, further studies are 
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required to establish optimal serum phosphate levels and evaluate safe and 
effective phosphate repletion regimens during acute RRT to prevent and treat 
RRT-induced hypophosphatemia. 
19.  Mohammad H. Alsumrain , Sami Abdul Jawad ,  Nashat B. Imran,  Sandeep 
Riar, Vincent A. DeBari , Marc Adelman in their  study investigated the 
association between hypophosphatemia and weaning failure in patients in two 
medical intensive care units (ICU) setup . The study was conducted in a 
prospectively developed cohort of 66 patients being treated with ventilatory 
support and in whom 193 weaning trials were attempted. Ultimately, all 66 
subjects were successfully weaned. A cross-sectional analysis was conducted on 
serum phosphorus levels and success or failure to wean the patients from 
ventilators.  
At the time of the successful weaning attempts (n = 66), the subjects’ serum 
phosphorus concentrations (mean ± SD) were 1.18 ± 0.27 mmol/L, whereas at 
all failed weaning attempts (n = 127) serum phosphorus concentrations were 
averaged 1.06 ± 0.31 mmol/L (p = 0.008). Subjects with phosphorus 
concentrations below the reference interval (RI) in our laboratory (<0.80 
mmol/L) had greater risk for weaning failure compared to subjects with 
phosphorus concentrations at or above the RI (relative risk = 1.18; 95% 
confidence interval = 1.06 to 1.32; p = 0.01).  
Serum calcium concentrations were not significantly different at the time of 
successful weaning compared to those at failed weaning attempts from the 
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mechanical ventilators. This study indicates that there is an association between 
hypophosphatemia and failure-to-wean from mechanical ventilation in ICU 
patients on ventilatory support. 
20. Thierry Charron, Francis Bernard, Yoanna Skrobik, Nathalie Simoneau, 
Nadine Gagnon, Martine Leblanc evaluated efficacy and safety of aggressive 
correction of hypophosphatemia with intravenous potassium phosphate in the 
ICU. Patients with moderate hypophosphatemia (<0.65 and 
>0.40 mmol/l; n=37) were randomized into two groups: group 1  who have 
received 30 mmol potassium phosphate intravenously in 50 ml saline over 2 h, 
and group 2  who have received 30 mmol potassium phosphate in 100 ml saline 
over 4 h. Patients with severe hypophosphatemia (<0.40 mmol/l; n=10) were 
also randomized into two groups: group 3 received 45 mmol potassium 
phosphate intravenously in 100 ml saline over 3 h, and group 4 received 
45 mmol potassium phosphate in 100 ml saline over 6 h. Electrolytes, blood gas, 
renal function were monitored until day 3; urine was collected during and until 
6 h after infusions. The overall efficacy of the protocols was 98% by the end of 
the infusion. There was no statistical difference in  the  phosphate values 
between groups at the end of infusion or at 24 h. No adverse events were noted 
during the study period ; one patient had an increase in serum potassium to 
6.1 mmol/l. Phosphaturia in all groups was elevated as evidenced by fractional 
excretion above 20%. More rapid administration of large potassium phosphate 
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boluses is effective and safe for correcting hypophosphatemia in ICU patients 
with preserved renal function if baseline serum potassium is below 4 mmol/l. 
21. Squara P , Bleichner G , Aubier M , Parent A , Sollet JP , Murciano 
D  observed that the hypophosphoremia may be interfering  with the respiratory 
function in chronic obstructive pulmonary diseases (COPD) through different 
mechanisms: muscular exhaustion and weakness. Accordingly, the frequency 
and magnitude of hypophosphoremia was studied in 36 consecutive patients 
with acute respiratory failure and mechanical ventilation. Initial phosphoremia 
was normal (1,32 +/- 0,12 mmol/l) but often and rapidly decreased in all patients 
after mechanical ventilation had been started (0,54 +/- 0,14 mmol/l after 24 h).  
 
After this, phosphoremia remained low, slowly increasing with continued 
enteral nutrition (2000 Kcal, 276 g of glucides, 33 mmol/l of phosphorus). Four 
patients had severe hypophosphoremia after the  24 h of mechanical ventilation 
(less than 0,30 mmol/l). Phosphoremia returned to a normal level 36 h after 
extubation. Hypophosphoremia was closely linked to pH improvement (r = + 
0,67, P less than 0,001) and was paralleled by a drop in phosphaturia, suggesting 
intra-cellular penetration of phosphorus ion . 
22. Laaban, jean-p. MD; grateau, gilles MD in their study they   assessed 
prospectively the variations of serum phosphorus concentration (P) after onset 
of mechanical ventilation (MV) in patients with chronic obstructive pulmonary 
disease (COPD) and acute respiratory acidosis. In 14 COPD patients, they  
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measured P, paco2, and ph, immediately before MV (H0), then one hour (H1), 
4 (H4), 7 (H7), 12 (H12), and 24 h (H24) after starting MV. Po4 was in or above 
the normal range in ten patients and below normal range in four patients. P 
decreased significantly (p < .001) after MV at H1, H4, H7, H12, and H24. 
Hypophosphatemia was present in all patients after MV, but was severe                  
(p < .3 mmol/L) in only two patients. There was a significant correlation (r = .56 
p < .01) between the decrease of the  P and the increase of ph after MV. 
Hypophosphatemia was a constant and early finding after institution of MV in 
COPD patients and was presumably related to an intracellular shift of P 
secondary to the correction of respiratory acidosis. 
 
23.In their study Camp MA, Allon M observed that although severe 
hypophosphatemia has been associated with significant morbidity, little 
quantitative information is available on the magnitude of the risk. The objective 
of this study was to determine the frequency and timing of severe 
hypophosphatemia, the relative risk associated with the various medical 
diagnoses, and the choice of therapy. Among 10,197 patients hospitalized over 
a 1-year period, the incidence of severe hypophosphatemia (serum phosphate 
less than or equal to 0.33 mmol/l) was 0.43%. The incidence was 0.91% in 
alcoholics, 2.42% in septic patients, 10.4% in patients with malnutrition, and 
14.6% in patients with diabetic ketoacidosis. The odds ratio for developing the 
metabolic abnormality was 4.2 (95% confidence interval 2.2-8.1) in alcoholics, 
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6.4 (1.9-18.9) in septic patients, 46.9 (16.6-125.6) in patients with diabetic 
ketoacidosis, and 60.7 (31.4-117.5) in malnourished patients.  
 
There was a 4-fold increase in mortality in patients with severe 
hypophosphatemia (18.2 vs. 4.6%; p less than 0.001). The metabolic 
abnormality was not recognized or was inappropriately treated in 42% of 
patients. Severe hypophosphatemia is a relatively common finding in 
hospitalized patients, especially in those with certain well-defined medical 
conditions. It is associated with the significant excess mortality.  And its 
recognition and treatment remain suboptimal.116 
 
24. Hypophosphatemia can lead to muscle weakness and respiratory and heart 
failure, but the mechanism is unknown till to date. To address this question, 
Pesta DH1 and colleagues noninvasively assessed rates of muscle ATP synthesis 
in hypophosphatemic mice by using in vivo saturation transfer [31P]-magnetic 
resonance spectroscopy. By using this approach, we found that basal and insulin-
stimulated rates of muscle ATP synthetic flux (VATP) and plasma inorganic 
phosphate (Pi) were reduced by 50% in mice with diet-induced 
hypophosphatemia as well as in sodium- 
dependent Pi transporter solute carrier family 34, member 1 (NaPi2a)-knockout 
(NaPi2a-/-) mice compared with their wild-type littermate controls.  
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Rates of VATP normalized in both hypophosphatemic groups after restoring 
plasma Pi concentrations. Furthermore, VATP was directly related to cellular and 
mitochondrial Pi uptake in L6 and RC13 rodent myocytes and isolated muscle 
mitochondria. Similar findings were observed in a patient with chronic 
hypophosphatemia as a result of a mutation in SLC34A3 who had a 50% 
reduction in both serum Pi content and muscle VATP After oral Pi repletion and 
normalization of serum Pi levels, muscle VATP completely normalized in the 
patient. Taken together, these data support the hypothesis that decreased muscle 
ATP synthesis, in part, may be caused by low blood Pi concentrations, which 
may explain some aspects of muscle weakness observed in patients with 
hypophosphatemia.117 
 
25. Phosphate imbalances or disorders have a high risk of morbidity and 
mortality in patients with chronic kidney disease. It is unknown if this finding 
extends to mortality in patients presenting at an emergency room with or without 
normal kidney function. 
A cross sectional analysis included all emergency room patients between 2010 
and 2011 at the In selspital Bern, Switzerland. A multivariable cox regression 
model was applied to assess the association between phosphate levels and in-
hospital mortality up to 28 days. 22,239 subjects were screened for the study.  
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Plasma phosphate concentrations were measured in 2,390 patients on hospital 
admission and were included in the analysis. 3.5% of the 480 patients with 
hypophosphatemia and 10.7% of the 215 patients with hyperphosphatemia died.  
 
In univariate analysis, phosphate levels were associated with mortality, age, 
diuretic therapy and kidney function (all p<0.001). In a multivariate Cox 
regression model, hyperphosphatemia (OR 3.29, p<0.001) was a strong 
independent risk factor for the mortality. Hypophosphatemia was not associated 
with mortality (p>0.05).  Hyperphosphatemia is associated with 28-day in-
hospital mortality in an unselected cohort of patients presenting in an emergency 
room.118 
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MATERIAL AND METHODOLOGY OF THE STUDY 
DESIGN: 
This is a single centre non-randomised prospective study in determining the 
incidence of hypophosphatemia and its predictors in a critically ill patient in ICU 
and  to assess the morbidity and mortality associated with hypophosphatemia. 
Inclusion criteria : 1.  ICU patients. 
                                    2.  Age more than 13yrs and less than 60yrs. 
Exclusion criteria   :   1. Age less than 13 yrs and more than 60yrs. 
                                    2.Non ICU patients 
STUDY PERIOD: 
Patients admitted in the ICU during the period of 6months, between October 
2016 to march 2017 were taken up for the study. 
 
STUDY CENTRE: 
This study was carried out in the Department of General Medicine, Thanjavur 
medical college hospital, Thanjavur , South India. 
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HISTORY, TREATMENT AND BLOOD INVESTIGATION  DETAILS: 
Appropriate medical and drug history were collected from the reliable 
informants. Drugs instituted for the patients during the hospital stay and the 
biochemical parameters  were collected from the drug chart. 
 
This observational descriptive study was conducted at thanjavur medical college 
and hospital during the period of six months. In this study fifty patients were 
included during a period of 6 months with effect from October 2016 to march 
2016. After the clearance of ethical committee, informed consent was taken from 
the participants.  
 
Patients admitted in ICU of thanjavur medical college & hospital , who satisfy 
the inclusion criteria  are studied with history, clinical examination, hemoglobin, 
random blood sugar, serum phophorous,  serum albumin,  serum calcium, serum 
creatinine, arterial blood gas analysis,  liver function test. Inclusion criteria being 
the patients admitted in intensive care unit of age more than 13 years and age 
less than 60 years, others are excluded. 
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In our study, normal serum phosphate level was 2.5 to 4.5mg/dl. A level below 
2.5mg/dl was taken as hypophosphatemia. Severe hypophosphatemia was taken 
as level of PO4 <1.5mg/dl. Patient’s serum phosphate level was checked 
randomly during the hospital stay to identify any decrease in serum phosphate 
levels. Serum phosphate was measured by using fullers automatic analyzer. 
Molybdate  reagent kit was used.  
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STATISTICAL ANALYSIS 
 
 
 
1. Age Distribution 
 
 
 
 
 
 
 
 
 
                              
INFERENCE: 
 
 
Among 50 patients , most of them  (36%) were under the age group of 51yrs to 
60 yrs 
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FIG.1 Age distribution
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 2.Gender Distribution 
 
 
 
 
 
 
 
                  
                                                    Table no 1 
 
 
 
 
 
 
 
 
INFERENCE: 
 
Among the total sample size of 50 ,18 (36%) were females and 32 (64%) were 
males. 
 
64%
36%
FIG.2 Gender distribution
male female
Gender Frequency  Percentage PO4 = <2.5 
Male  32  64% 3 (9%) 
Female  18  36% 1 (5%) 
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3.Distribution of co morbidities among the study population 
 
 
 
 
 
 
INFERENCE: 
 
• Among the study population most of them were diabetic and 
hypertensive patients. 
• 39 patients were anaemic. 
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Fig.3 Distribution of co-morbidities
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4. Prevalence of hypophosphatemia in the study 
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FIG.4 Distribution of phosphate levels in a study population
hypophosphatemia
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Table.2. Distribution of phosphate levels in a study population 
 
Phosphate level Frequency  Percentage  
<2.5 4    8% 
2.5-4.5 35 70% 
>4.5 11  22% 
 
 
INFERENCE: 
  
• 8% of the study population have hypophosphatemia. 
 
 
 
 
5. Phosphate level and age distribution: 
 
                              Table 3: Phosphate level and age distribution 
PO4 (mg/dl) level        
 <40 years 
 
 >40years 
PO4 = < 2.5 1 3 
PO4 = >2.5 29 17 
 
 
 
INFERENCE: 
 
• Among 4 hypophosphatemic patients , 3 were over the age of 40. 
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6. Distribution of comorbidities among hypophosphatemic patients 
 
 
 
       
 
 
 
  
DIABETIC, 2
ALCOHOLIC, 2
COPD, 1
LIVER DISEASE, 2
CKD, 1
SEIZURE, 1
Fig.5 Distribution of co morbidities among hypophosphatemic 
patients.
DIABETIC ALCOHOLIC COPD LIVER DISEASE CKD SEIZURE
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Table 4: Distribution of comorbidities among hypophosphatemic patients 
 
Comorbidities  Frequency  PO4 = <2.5 P value 
Diabetic  15 (22%) 2 (13%) 0.3 
Alcoholic  12 (17%) 2 (16%) 0.2 
COPD  2 (3%) 1  (50%) 0.02 
Liver disease  5 (7%) 2 (40%) 0.005 
CKD  9 (13%) 1 (11%) 0.7 
 
 
INFERENCE: 
Among the 4 hypophosphatemia patients  
• 2  were decompensated chronic liver disease, 1was COPD, 1 was diabetic 
ketoacidosis. 
 All 4 were on mechanical ventilators. 
• 2 out of 4 were alcoholics. 
• 3 out of 4 expired. 
• Correlation between hypopohosphatemia and COPD ( P value = 0.02)  , 
liver disease  (P value = 0.005)  is statistically significant. 
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7. Frequency of hypophosphatemia in mechanically ventilated patients 
 
 
 
 
Table 5: Frequency of hypophosphatemia in mechanically ventilated patients 
 
Number of patients on 
mechanical ventilation 
PO4 = <2.5  PO4 = >2.5 P value 
23 (46%) 4 (17%) 19 (83%) 0.03 
 
 
 
 
 
 
INFERENCE: 
 
• Statistically significant (P value = 0.03) correlation is observed between 
the incidence of hypophosphatemia and mechanically ventilated patients. 
 
 
PO4 =<2.5
17%
PO4 =>2.5
83%
Fig.6 Prevalance of hypophosphatemia among patients on 
mechanical ventilation 
PO4 =<2.5 PO4 =>2.5
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8. Prevalence of hypophosphatemia in different treatment modalities 
 
 
Table:6  Prevalence of hypophosphatemia in different treatment modalities 
 
Treatment Frequency  PO4 = < 2.5 
Insulin 7 (14%) 1  
Beta – agonist  3 (6%) 1 
Inotropes 10 (20%) 1   
Dextrose  4 (8%) 2 
Diuretics  6 (12%) 1 
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FIG 7 Hypophosphatemia in different treatment 
modalities
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Table 7. Analysis of PO4, Hb, calcium 
 
 PO4 (mg/dl) Frequency  
Anemia <2.5  
>2.5 
2  (5%) 
37 (95%) 
Hypocalcemia  <2.5  
>2.5 
4  (8%) 
42 (92%) 
 
 
 
 
 
 
 
INFERENCE: 
 
• 2 (5%) of the anaemic patients have hypophosphatemia. 
• 4 (8%) of the hypocalcemic patients have hypophosphatemia. 
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Table 8. Frequency of mortality and hypophosphatemia 
 
Deaths  PO4 level(mg/dl) Frequency  Percentage  
14 < 2.5 
2.5 – 4.5 
>4.5 
3 
4 
7 
21% 
29% 
50% 
 
 
 
 
 
 
 
 
 
 
INFERENCE: 
• Statistically significant correlation is observed between 
hypophosphatemia and mortality. 
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RESULTS: 
 
1. Fifty patients including both genders were included in the study conducted at 
Thanjavur medical college , hospital, Thanjavur during the period of  6 
months from October  2016 to March 2017. 
2. In our study the age range was 15-60 years. Sixty four percent (64%) were 
male patients and thirty percent (36%) were female with male to female ratio 
1.7:1. 
3. 35% of the study population were the elderly from 51-60 years.  
4. Most of the study population were diabetic patients (22%) and hypertensives 
(20%) occupying 42%.  
5. 78% of the study group were anaemic. 
6. In this study, serum phosphate concentration was in the range of 1.6 to 11.3 
mg/dl.  
7. Out of 50 patients,  (4)  8% had hypophosphatemia , 70% had normal 
phosphate levels, 22% had hyperphosphatemia. 
8. Out of 4 hypophosphatemic patients, 3 were over the age of 40yrs, 2  had 
decompensated chronic liver disease, 1had COPD, 1 had diabetic 
ketoacidosis. 2 of them were alcoholics. 
 
77 
 
9. 9% of the males and 5% of the females had hypophosphatemia.  
10. All 4 were on mechanical ventilators.  
11. 20% and 14% of the patients were on inotropes and insulin respectively. 
12. In our study 3 patients who  died had hypophosphatemia along with other 
disease. 
13. 79% of the mortality was seen in the patients who had serum phosphate level 
more than 2.5 mg/dl. 
14. 50% of the mortality occurred among the patients who had phosphate level 
more than 4.5mg/dl. 
15. Correlation between hypopohosphatemia and COPD ( P value = 0.02)  , liver 
disease  (P value = 0.005)  is statistically significant. 
16. Statistically significant (P value = 0.03) correlation is observed between the 
incidence of hypophosphatemia and mechanically ventilated patients. 
17. Statistically significant correlation is observed between hypophosphatemia 
and mortality. 
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DISCUSSION 
 
In a study reported by Geerse the critically ill patients have a high prevalence of 
hypophosphatemia because of the presence of multiple causal factors. 
Hypophosphatemia may lead to a multitude of symptoms, but most often 
remains asymptomatic. Hypophosphatemia, however, is associated with 
increased mortality in important patient subgroups. It is important to investigate 
whether hypophosphatemia causes higher mortality in itself, or rather is 
associated with a higher severity of illness95.  
In another study reported by Betro and Pain96 the prevalence of 
hypophosphatemia of 2 to 5% in hospitalized patients which increased to 20 to 
40% if predisposing conditions such as alcoholism, diabetic ketoacidosis, 
recovery from burns or sepsis were present. In our study the prevalence of 
hypophosphatemia was 8% with predisposing conditions. History of alcoholism 
was found in 17% our patients.  
Fischer et al 97 described low phosphate levels (<2.5mg/dl) in 25% of patients in 
respiratory illness with a 5% prevalence of severely reduced serum levels 
(<1.0mg/dl). In our study severe (<1.5mg/dl) hypophosphatemia was not found. 
Another study carried out by Fiaccardori et al98 22 patients with chronic 
obstructive pulmonary disease. Phosphorus content was measured by 
spectrophotometric methods on muscle fragments of both peripheral and 
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respiratory muscles. Thirty age and sex matched subjects were used as controls. 
Muscle phosphorus depletion was present in about 50% of patients with COPD. 
Mean age was 63±6 years with 19 men, 3 women.  
In our study 2 ( 3%) patients had chronic obstructive pulmonary disease. Muscle 
phosphorus was not measured. Hypophosphatemia was present in 1 patient of 
COPD. There were 32 male and 18 patients were female in our study. There was 
no control used. One  patient was  on total parenteral nutrition. Paleologos 99 in 
a study reported significant lowering of serum phosphate levels after 
hyperventilation and dextrose infusion (p<0.0003). In our study serum 
phosphate levels however, were not measured after dextrose loading in our 
study.  
Severe hypophosphatemia may cause acute respiratory failure, myocardial 
depression or seizures as described by Miller2 in emergency department with 
alcoholic patients. In our study one patient with serum phosphate levels of 
1.6mg/dl had respiratory failure. 
In a retrospective analysis by Ornstein21 to determine the incidence of 
hypophosphatemia in adolescents with anorexia nervosa, sixty nine patients (66 
females, 3 male) with anorexia nervosa were included. Mean age was 15.5±2.5. 
Four (5.8%) developed moderate hypophosphatemia (<2.5mg/dl >1.0mg/dl), 
fifteen (21.7%) had mild hypophsphatemia (<3.0mg/dl & >2.5mg/dl). 
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Phosphorus nadirs were directly proportional to ideal body weight (p 0.01). In 
our study 2 (4%) patients developed moderate hypophosphatemia.  
A study carried out by Bollaert100 study done to see the haemodynamic and 
metabolic effects of rapid correction of hypophosphatemia in patients with septic 
shock, phosphorus administration was followed by a 22% increase in left 
ventricular stoke work index (p <0.01) and a 12% increase in systolic arterial 
pressure, while in our study no effects on haemodynamics were studied.  
 
Limitations of the study:   
• Few sample size 
• Single, random serum phosphorous sample was taken. 
• Few variables were compared. 
• Phosphorous repletion  was not included in the study.. 
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SUMMARY 
Hypophosphatemia is one of the electrolyte abnormality that has been 
frequently neglected and overlooked in the ICU setup. Since this abnormality 
has been associated with increased hospital stay, cardiac dysfunction, respiratory 
failure it should be always kept in mind when we come across weaning failure 
or refractory cardiogenic shock. Critically ill patients are themselves prone to 
devolep hypophosphatemia. It occurs in certain morbid conditions like COPD, 
diabetic ketoacidosis, alcoholics, liver disease patients. Treating this 
abnormality will revert the complication and reduce the morbidity and mortality 
associated with hypophosphatemia. 
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CONCLUSION 
Hypophosphatemia observed in chronic obstructive pulmonary disease, liver 
disease  and in mechanically ventilated patients and it is statistically significant. In a 
critically ill -patients, Hypophosphatemia is a predictor of respiratory failure and 
mortality. So some place should be reserved for serum phosphate levels in ICU blood 
investigation panels. 
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A1. PROFORMA 
 
 
GUIDE: PROF.D.NEHRU. M.D., MDRD                 
 INVESTIGATOR: DR.SELWYN SELVA KUMAR.D 
 
TITLE:   A study on Hypophosphatemia in  critically ill patients in ICU – its incidence 
and predictors in Thanjavur medical college and hospital. 
 
Name:                                                      IP NO:                                    Age/sex: 
 
Address: 
 
Diagnosis: 
 
Co- morbidity:        yes / no.    If yes:       a) diagnosis 
                                                                     b)  duration. 
                                                                     c)  treatment.         
(1.Diabetes mellitus. 2.Systemic hypertension.3. Alcoholic.4. Bronchial asthma    
5. COPD  6. Liver disease  7. CKD   8. Heart failure  9. Malignancy 10.seizures ) 
 
  
  
DRUG HISTORY: Yes/no 
 1.steroid.2.Insulin 3. Beta agonist 4. Inotropes. 5. Antacids 6. Dextrose  
7. Diuretic 
 
INVESTIGATIONS 
1. S.Phosphorous:  
2. Hemoglobin: 
3. RBS: 
4. S.calcium: 
5. S.creatinine 
6. Liver function test:    OT/PT-           TSB-             ALP- 
7. pH 
 
TOTAL PARENTERAL   NUTRITION  : yes/no , if yes : duration....................        
 
MECHANICAL VENTILATION           : yes /no , if yes : duration .................... 
                                                                                          :  weaning failure  (yes/no) 
 
 DURATION OF STAY IN ICU ON THE DAY OF SAMPLING: 
 
SURVIVOR / NON SURVIVOR  : 
 
  
  
 
A2.CONSENT FORM 
 
 
I __________________________________________  hereby give consent to 
participate in the study conducted by DR.SELWYN SELVA KUMAR.D,  Post 
graduate in the Department of  General Medicine ,Thanjavur Medical College & 
Hospital, Thanjavur – 613004 and to use my personal clinical data and result of 
investigation for the purpose of analysis and to study the nature of disease. I also give 
consent for further investigations 
 
 
 
 
 
 
Place : 
Date :       Signature of participant 
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ெபய : 
 
வய : 
 
பாலின : 
 
கவ: 
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ஆ%வி  ெவளியிட ஆ2ேசபைண இைல எ'! ெதவி 
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1 elangovan 21888 36 m ckd 5 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 5.2 4.5 136
2 prema 23117 21 f primi/dic/aki 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 9.5 8.6 119
3 deivani 22193 52 f copd/pul htn/res.fail 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 2.5 13.4 148
4 rani 22872 55 f dm2/dka 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 3.6 8.8 538
5 tamilarasi 23760 55 f dm2/cad/evovled awmi 1 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 3 9.6 372
6 murugayee 23503 41 f rhd/dvr/cardiogenic shock 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 1 3 7.4 72
7 sathiyamoorthy 23720 34 m dcld/hepatic ence 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 1 1 11.3 9 52
8 ranjani 23797 22 f fever with thrombocytopenia 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3.5 8.7 118
9 mahendran 23824 45 m meningoencephalitis 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4.3 8.8 103
10 ramya 24256 22 f primipara/cvt/rf 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 3.9 14.7 86
11 sathishkumar 23408 34 m ckd 5 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 9.6 6.8 128
12 subramani 24433 60 m dka 1 1 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 3.4 8 484
13 ravichandran 24335 55 m dcld 1 0 1 0 0 1 1 0 0 1 0 0 0 0 0 1 0 2.5 5.2 498
14 vijay 23818 40 m dka 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1.6 14.1 534
15 malliga 24554 60 f cad 1 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 3.3 10.2 509
16 laksmanan 24871 59 m hf 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 3.6 12.6 124
17 nithya 25066 18 f tb mining 0 0 0 0 0 1 0 0 0 1 1 0 0 0 0 0 0 3.8 9.2 242
18 bala 25403 45 m dcld 0 0 1 0 0 1 0 0 0 0 0 0 0 1 0 1 1 2 8.4 135
19 ganesan 25642 59 m multi infarct 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 2.8 9.2 285
20 subramani 25691 55 m ckd 5 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 3.6 5.2 40
21 kannaiyan 23391 60 m cva 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3.1 9 88
22 chinnappa 25794 50 m ckd 5 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 4.6 6.6 68
23 kather 26082 65 m dka 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 4.8 9 151
24 arul 25672 37 m ild 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 1 0 5 12.6 136
25 rajangam 25647 53 m tuberculoma 0 0 1 0 0 1 0 0 0 0 1 0 0 1 0 0 0 3.4 10.4 85
26 paulraj 26185 60 m seizure 0 1 0 1 0 0 0 0 0 1 1 0 1 0 0 0 0 3 8.6 233
27 rajinamary 26210 58 f seizure 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5.6 8.8 74
28 saravannan 26850 45 m hypoglycemia 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2.7 10.1 102
29 arun 25386 18 m rat killer paste 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3.3 9.8 83
30 palani 26341 43 m rat killer paste 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 12.8 60
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31 rao 25995 60 m zolpidem poisoning 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2.7 11.4 155
32 ilayaraja 23421 35 m opc pois 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2.6 9.2 100
33 abhinaya 26834 21 f ppc 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 3.9 13.2 110
34 janarthan 25919 60 m sepsis 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3.3 10 65
35 philip 26868 15 m hanging 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3.4 11.4 74
36 udhay 27155 31 m resp.fail 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 10.8 74
37 raman 27004 60 m sepsis 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 3.5 8.8 384
38 beevi 27489 22 f sle 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 5.2 6.9 93
39 ram 27626 52 m dka 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3.1 13.6 499
40 saroja 27855 55 f cad 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 5.4 7.4 141
41 rosy 23487 39 f ckd 5 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 4.9 8.6 63
42 shanthi 28292 27 f pcm 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3.6 13 109
43 nagappan 28631 60 m ptb 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3.1 6.1 196
44 madhavi 27373 16 f sle 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 3.4 6.8 105
45 balaji 28765 34 f dka 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 3 11.6 230
46 igbal 28941 55 m cva 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4.3 12.4 122
47 meera 28541 37 m cva 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3.1 9.8 149
48 vijaya 27371 37 f hanging 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 3.1 6.4 122
49 thambiraj 28768 60 m copd/pul htn/res.fail 0 0 0 0 1 0 0 1 0 0 0 0 0 1 0 0 0 2.8 8.5 71
50 baskar 28973 30 m hanging 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3.8 8.8 75
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5.2 7.1 6.1 34 29 1 36 7.2 138 3.5 0 1 0 2 0 2
9.5 6 4.7 350 470 1.2 86 7.3 136 4.9 3 1 0 3 0 2
2.5 6.2 0.9 38 40 0.9 30 7.6 136 2 0 1 1 4 0 4
3.6 7.7 2.3 58 38 0.9 40 7.1 133 3.4 0 0 0 0 1 4
3 7.8 0.9 200 210 1.2 160 7.5 139 3.8 0 0 0 0 1 3
3 8.6 0.7 32 26 1.1 66 7.5 135 3.9 0 0 0 0 1 3
11.3 7.6 3.1 110 45 12 25 7.3 120 2.8 0 1 0 2 0 2
3.5 7.6 0.6 51 61 0.9 33 7.4 130 4.5 0 0 0 0 1 2
4.3 7.1 1.2 85 28 1.1 73 7.5 130 3.3 0 0 0 0 0 1
3.9 7 1.8 40 22 0.8 62 7.5 132 3.2 3 1 0 3 0 3
9.6 5.2 10.6 27 20 0.9 79 7.48 138 3.8 0 0 0 0 1 5
3.4 7.4 1 44 28 1 77 7.39 149 2.4 0 0 0 0 1 2
2.5 7.1 2.9 240 120 5.3 328 7.45 130 2.9 0 1 0 1 1 1
1.6 9 3.3 71 60 1 190 7.42 132 3.5 0 1 0 2 0 2
3.3 8.2 3.6 40 20 1.1 35 7.3 136 4.3 0 0 0 0 1 2
3.6 8 3.6 45 22 1 42 7.35 141 3.3 0 0 0 0 1 2
3.8 7.9 1.1 99 41 62 62 7.2 144 2.1 0 1 0 2 1 3
2 5.9 2.8 41 28 6.8 173 7.5 132 3.9 0 1 0 3 0 3
2.8 9.2 1.8 87 39 1 77 7.5 135 2.2 0 1 0 1 0 1
3.6 7.7 6.6 40 36 1 50 7.2 132 3.8 0 0 0 0 1 2
3.1 7.4 1 39 40 1 40 7.5 134 3.2 0 1 1 8 0 8
4.6 7.6 4.7 68 40 0.9 52 7.4 132 4 0 0 0 0 1 2
4.8 7.4 4.5 25 19 1 356 7.3 136 3 0 0 0 0 1 2
5 7.1 1.6 160 210 4.2 51 7.32 130 4.6 0 1 0 3 1 3
3.4 7.2 0.9 118 160 8.2 90 7.5 135 3.3 0 1 1 4 0 4
3 7.8 1.5 40 45 1.4 37 7.4 132 3.1 0 1 0 3 1 3
5.6 7 0.9 40 32 0.9 36 7.5 155 3.9 0 0 0 0 0 3
2.7 8 2.5 50 34 1 31 7.4 133 3.2 0 1 0 3 0 3
3.3 9.7 0.8 220 260 6.2 136 7.9 127 3.9 0 0 0 0 1 8
3 8.1 0.8 80 60 2.8 45 7.4 130 1.9 0 0 0 0 1 3
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2.7 8.7 1 27 30 0.9 83 7.5 127 2.7 0 1 1 6 0 5
2.6 7.8 0.9 51 48 1 69 7.4 127 2.4 0 1 1 15 1 17
3.9 8.9 1.4 33 32 1 79 7.4 148 3.9 0 1 0 3 1 2
3.3 9.2 1.1 240 210 3.8 167 7.3 150 4.6 0 1 0 2 1 1
3.4 9.1 0.8 40 39 1 30 7.39 144 4.5 0 1 0 3 1 3
4 8 0.7 48 35 1 49 7.4 139 4.4 0 0 0 0 1 3
3.5 8.1 1.8 43 20 0.9 70 7.4 125 2.4 0 0 0 0 1 4
5.2 7.7 5.7 49 20 1 50 7.2 138 3.5 0 0 0 0 1 2
3.1 8.4 2.3 37 20 1 50 7.4 116 2 0 0 0 0 1 2
5.4 7.6 12.6 50 40 1 42 7.1 147 4.4 0 0 0 0 1 2
4.9 8.2 3.3 40 40 1 32 7.4 124 3.7 0 0 0 0 1 2
3.6 7.9 0.8 69 57 1 30 7.5 132 3.2 0 0 0 0 1 2
3.1 7 0.6 36 20 0.9 388 7.4 135 3.4 0 0 0 0 1 2
3.4 8.5 0.5 33 25 0.8 43 7.5 38 4.6 0 0 0 0 1 2
3 8.3 2.4 40 70 1 122 7.5 151 4 $$$ 1 1 5 1 5
4.3 5.9 1.5 40 30 1 103 7.4 160 3.9 0 1 0 2 1 2
3.1 7.2 23 79 41 1 42 7.5 152 3.5 0 1 0 3 0 4
3.1 6.9 0.8 18 25 0.8 37 7.6 144 3.2 0 1 1 8 1 8
2.8 5 1 160 110 1 33 7.3 139 4 0 0 0 1 1 1
3.8 6.1 0.6 35 60 1 28 7.42 148 3.3 0 0 0 2 1 2
